These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36975364)

  • 1. Comparative Binding Ability of Human Monoclonal Antibodies against Omicron Variants of SARS-CoV-2: An
    Das NC; Chakraborty P; Bayry J; Mukherjee S
    Antibodies (Basel); 2023 Feb; 12(1):. PubMed ID: 36975364
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Das NC; Chakraborty P; Bayry J; Mukherjee S
    Front Immunol; 2021; 12():782506. PubMed ID: 35082779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3.
    Huang M; Wu L; Zheng A; Xie Y; He Q; Rong X; Han P; Du P; Han P; Zhang Z; Zhao R; Jia Y; Li L; Bai B; Hu Z; Hu S; Niu S; Hu Y; Liu H; Liu B; Cui K; Li W; Zhao X; Liu K; Qi J; Wang Q; Gao GF
    Immunity; 2022 Aug; 55(8):1501-1514.e3. PubMed ID: 35777362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined Antibodies Evusheld against the SARS-CoV-2 Omicron Variants BA.1.1 and BA.5: Immune Escape Mechanism from Molecular Simulation.
    Zhang J; Cong Y; Duan L; Zhang JZH
    J Chem Inf Model; 2023 Aug; 63(16):5297-5308. PubMed ID: 37586058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neohesperidin and spike RBD interaction in omicron and its sub-variants: In silico, structural and simulation studies.
    Singh JK; Dubey S; Srivastava G; Siddiqi MI; Srivastava SK
    Comput Biol Med; 2023 Jan; 152():106392. PubMed ID: 36502697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico study of SARS-CoV-2 spike protein RBD and human ACE-2 affinity dynamics across variants and Omicron subvariants.
    Abeywardhana S; Premathilaka M; Bandaranayake U; Perera D; Peiris LDC
    J Med Virol; 2023 Jan; 95(1):e28406. PubMed ID: 36519577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal antibodies against S2 subunit of spike protein exhibit broad reactivity toward SARS-CoV-2 variants.
    Ko SH; Chen WY; Su SC; Lin HT; Ke FY; Liang KH; Hsu FF; Kumari M; Fu CY; Wu HC
    J Biomed Sci; 2022 Dec; 29(1):108. PubMed ID: 36550570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response.
    Patel A; Kumar S; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Bajpai P; Raju DR; Edara VV; Davis-Gardner ME; Linderman S; Dixit K; Sharma P; Mantus G; Cheedarla N; Verkerke HP; Frank F; Neish AS; Roback JD; Davis CW; Wrammert J; Ahmed R; Suthar MS; Sharma A; Murali-Krishna K; Chandele A; Ortlund EA
    bioRxiv; 2022 Oct; ():. PubMed ID: 36324804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biparatopic antibody BA7208/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5.
    Wang Y; Yan A; Song D; Dong C; Rao M; Gao Y; Qi R; Ma X; Wang Q; Xu H; Liu H; Han J; Duan M; Liu S; Yu X; Zong M; Feng J; Jiao J; Zhang H; Li M; Yu B; Wang Y; Meng F; Ni X; Li Y; Shen Z; Sun B; Shao X; Zhao H; Zhao Y; Li R; Zhang Y; Du G; Lu J; You C; Jiang H; Zhang L; Wang L; Dou C; Liu Z; Zhao J
    Cell Discov; 2023 Jan; 9(1):3. PubMed ID: 36609558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Most frequently harboured missense variants of hACE2 across different populations exhibit varying patterns of binding interaction with spike glycoproteins of emerging SARS-CoV-2 of different lineages.
    Tahsin A; Ahmed R; Bhattacharjee P; Adiba M; Al Saba A; Yasmin T; Chakraborty S; Hasan AKMM; Nabi AHMN
    Comput Biol Med; 2022 Sep; 148():105903. PubMed ID: 35932731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Screening of Bioactive Compounds of Representative Seaweeds to Inhibit SARS-CoV-2 ACE2-Bound Omicron B.1.1.529 Spike Protein Trimer.
    Bharathi M; Sivamaruthi BS; Kesika P; Thangaleela S; Chaiyasut C
    Mar Drugs; 2022 Feb; 20(2):. PubMed ID: 35200677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural insights for neutralization of Omicron variants BA.1, BA.2, BA.4, and BA.5 by a broadly neutralizing SARS-CoV-2 antibody.
    Kumar S; Patel A; Lai L; Chakravarthy C; Valanparambil R; Reddy ES; Gottimukkala K; Davis-Gardner ME; Edara VV; Linderman S; Nayak K; Dixit K; Sharma P; Bajpai P; Singh V; Frank F; Cheedarla N; Verkerke HP; Neish AS; Roback JD; Mantus G; Goel PK; Rahi M; Davis CW; Wrammert J; Godbole S; Henry AR; Douek DC; Suthar MS; Ahmed R; Ortlund E; Sharma A; Murali-Krishna K; Chandele A
    Sci Adv; 2022 Oct; 8(40):eadd2032. PubMed ID: 36197988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of antiviral peptide inhibitors for receptor binding domain of SARS-CoV-2 omicron and its sub-variants: an in-silico approach.
    Singh S; Banavath HN; Godara P; Naik B; Srivastava V; Prusty D
    3 Biotech; 2022 Sep; 12(9):198. PubMed ID: 35923684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational strategies for enhancing mAb binding to SARS-CoV-2 variants through CDR diversification and antibody-escape prediction.
    Shah M; Shin JY; Woo HG
    Front Immunol; 2023; 14():1113175. PubMed ID: 37063859
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular dynamics simulations highlight the altered binding landscape at the spike-ACE2 interface between the Delta and Omicron variants compared to the SARS-CoV-2 original strain.
    Pitsillou E; Liang JJ; Beh RC; Hung A; Karagiannis TC
    Comput Biol Med; 2022 Oct; 149():106035. PubMed ID: 36055162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of new SARS-CoV-2 variant Omicron (B.1.1.529) on vaccine efficacy, its correlation to Delta variants: A computational approach.
    Ranjan P; Neha ; Devi C; Devar KA; Das P
    Microb Pathog; 2022 Aug; 169():105619. PubMed ID: 35690234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.
    Jawad B; Adhikari P; Podgornik R; Ching WY
    Comput Biol Med; 2023 Dec; 167():107576. PubMed ID: 37871435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.